文献速递肝病

瑞典肝硬化患者的临床病程与病因别死亡率:一项基于人群的1317例患者长期随访研究

Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.
PubMed 文献 · Aliment Pharmacol Ther · 2019-04-08

该研究基于瑞典斯科讷地区2001年1月至2010年12月诊断的1317例肝硬化患者,随访至2017年12月,比较不同病因的临床病程、生存模式和死亡原因。结果显示肝硬化病程和生存率因病因和诊断时状态差异很大,酒精性肝硬化10年累计失代偿发生率为89%,丙型肝炎为58%,隐源性肝硬化为75%。

要点

  • 诊断时失代偿是除酒精性肝硬化外所有病因死亡的重要预测因素。
  • 隐源性肝硬化10年无移植生存率最低(11%),酒精性肝硬化18%,酒精合并丙型肝炎12%。
  • 自身免疫性肝炎肝硬化10年生存率最高(53%),其他病因平均约30%。

核心结论

  • 肝硬化临床病程和生存率因病因和诊断时状态差异很大。

研究设计与样本

  • 基于人群的队列研究,使用瑞典斯科讷地区2001年1月至2010年12月诊断的肝硬化患者医学登记和病历复习,随访至2017年12月,共纳入1317例患者。

主要发现

  • 队列中631例诊断时已失代偿,387例随访期间失代偿;991例死亡,91例接受移植。
  • 10年累计失代偿发生率(以死亡和移植为竞争风险):酒精性肝硬化89%,丙型肝炎58%,隐源性肝硬化75%。
  • 10年无移植生存率最低为隐源性肝硬化11%、酒精性肝硬化18%、酒精合并丙型肝炎12%。
  • 自身免疫性肝炎肝硬化10年生存率最高为53%,丙型肝炎、非酒精性脂肪性肝炎、原发性胆汁性胆管炎、原发性硬化性胆管炎及其他病因平均约30%。
  • 诊断时失代偿是除酒精性肝硬化外所有病因死亡的重要预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver cirrhosis is characterized by a silent phase until decompensation, which is defined by ascites, bleeding from esophageal varices or hepatic encephalopathy. AIM: To compare the clinical course, patterns of survival and causes of death by etiology during long-term follow-up in a large population-based cohort of patients with incident cirrhosis. METHODS: We used population-based medical registries for a cohort study of patients with liver cirrhosis diagnosed January 2001 to December 2010, in the Scania region of Sweden. Medical records were reviewed. Patients were classified according to etiology and clinical parameters were registered. Patients were followed until December 2017. RESULTS: The cohort comprised 1317 patients, 631 were decompensated at diagnosis and 387 decompensated during follow-up. The cumulative 10-year incidence of decompensation, with death and transplantation as competing risks, was 89% in alcoholic cirrhosis, 58% in hepatitis C and 75% in cryptogenic cirrhosis. The lowest 10-year transplantation-free survival rates were found in cryptogenic cirrhosis (11%), alcohol-related cirrhosis (18%) and alcohol combined with hepatitis C (12%). Autoimmune hepatitis cirrhosis showed the best 10-year survival (53%) and hepatitis C, non-alcoholic steatohepatitis, primary biliary cholangitis, and primary sclerosing cholangitis and other causes averaged 30%. Decompensation at diagnosis was an important predictor for death in all etiologies apart from alcoholic cirrhosis. 991 patients died and 91 were transplanted. CONCLUSION: Our results show that the clinical course and survival in cirrhosis differ considerably by both etiology and state at diagnosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nilsson E, Anderson H, Sargenti K, et al. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther. 2019. PMID: 30957910. doi:10.1111/apt.15255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。